Suppr超能文献

研究低玻璃化转变温度赋形剂在共研磨中最小化磺胺嘧啶非晶化能力。

Investigation of the capacity of low glass transition temperature excipients to minimize amorphization of sulfadimidine on comilling.

机构信息

School of Pharmacy and Pharmaceutical Sciences, University of Dublin, Trinity College Dublin, Dublin 2, Ireland.

出版信息

Mol Pharm. 2013 Jan 7;10(1):386-96. doi: 10.1021/mp300529a. Epub 2012 Dec 5.

Abstract

The coprocessing of active pharmaceutical ingredient (API) with an excipient which has a high glass transition temperature (T(g)) is a recognized strategy to stabilize the amorphous form of a drug. This work investigates whether coprocessing a model API, sulfadimidine (SDM) with a series of low T(g) excipients, prevents or reduces amorphization of the crystalline drug. It was hypothesized that these excipients could exert a T(g) lowering effect, resulting in composite T(g) values lower than that of the API alone and promote crystallization of the drug. Milled SDM and comilled SDM with glutaric acid (GA), adipic acid (AA), succinic acid (SA), and malic acid (MA) were characterized with respect to their thermal, X-ray diffraction, spectroscopic, and vapor sorption properties. SDM was predominantly amorphous when milled alone, with an amorphous content of 82%. No amorphous content was detected by dynamic vapor sorption (DVS) on comilling SDM with 50% w/w GA, and amorphous content of the API was reduced by almost 30%, relative to the API milled alone, on comilling with 50% w/w AA. In contrast, amorphization of SDM was promoted on comilling with 50% w/w SA and MA, as indicated by near-infrared (NIR) spectroscopy. Results indicated that the API was completely amorphized in the SDM:MA comilled composite. The saturated solubility of GA and AA in the amorphous API was estimated by thermal methods. It was observed that the T(g) of the comelt quenched composites reached a minimum and leveled out at this solubility concentration. Maximum crystallinity of API on comilling was reached at excipient concentrations comparable to the saturated concentration solubility of excipient in the API. Moreover, the closer the Hildebrand solubility parameter of the excipient to the API, the greater the inhibition of API amorphization on comilling. The results reported here indicate that an excipient with a low T(g) coupled with high solubility in the API can prevent or reduce the generation of an amorphous phase on comilling.

摘要

将活性药物成分 (API) 与玻璃化转变温度 (T(g)) 较高的赋形剂共处理是稳定药物无定形形式的一种公认策略。本工作研究了将模型 API 磺胺嘧啶 (SDM) 与一系列低 T(g) 赋形剂共处理是否可以防止或减少结晶药物的无定形化。假设这些赋形剂可以发挥 T(g) 降低作用,导致复合 T(g) 值低于单独 API,并促进药物结晶。对研磨的 SDM 和与戊二酸 (GA)、己二酸 (AA)、琥珀酸 (SA) 和苹果酸 (MA) 共研磨的 SDM 进行了热、X 射线衍射、光谱和蒸汽吸附特性的表征。当单独研磨时,SDM 主要为无定形,无定形含量为 82%。通过动态蒸汽吸附 (DVS) 检测到与 50% w/w GA 共研磨的 SDM 无无定形含量,与单独研磨的 API 相比,API 的无定形含量减少了近 30%。相比之下,在与 50% w/w SA 和 MA 共研磨时,SDM 的无定形化得到了促进,这表明近红外 (NIR) 光谱。结果表明,API 在 SDM:MA 共研磨复合材料中完全无定形。通过热法估计了 GA 和 AA 在无定形 API 中的饱和溶解度。观察到共熔体淬火复合材料的 T(g) 达到最小值并在该溶解度浓度下趋于稳定。在与赋形剂在 API 中的饱和溶解度浓度相当的浓度下共研磨时,API 的结晶度达到最大值。此外,赋形剂的 Hildebrand 溶解度参数越接近 API,API 的无定形化抑制作用就越大。这里报道的结果表明,具有低 T(g) 且与 API 高溶解度的赋形剂可以防止或减少共研磨时无定形相的产生。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验